Utama › Leukemia Mieloid Akut › Maryland
Kajian klinikal Leukemia Mieloid Akut di Maryland
31 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi di Maryland.
Bandar di Maryland
Teks kajian rasmi (Bahasa Inggeris)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06904066Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- dan 10 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Center for Cancer and Blood Disorders, Bethesda
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06398457Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05554406A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Johns Hopkins University, Baltimore
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- dan 1 lagi
Mengambil pesertaFasa 3
6 Months – 21 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- John Hopkins School of Medicine, Baltimore
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06824168The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1/2Sukarelawan sihat dialu-alukan
Umur 12 hingga 120 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT05436418Longitudinal Studies of Patient With FPDMM
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
1 Day – 100 Years · Semua jantina · Dikemas kini 11 Sep 2026 · NCT03854318A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- The Center for Cancer and Blood Disorders, Bethesda
Mengambil pesertaKajian pemerhatian
Umur 0 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07154823Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Baltimore MD-UMGCCC, Baltimore
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Baltimore MD-UMGCCC, Baltimore
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07223814A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Maryland/Greenebaum Cancer Center, Baltimore
Mengambil pesertaFasa 1
Umur 18 hingga 75 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1
Umur 3 hingga 35 · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT02390752Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
- Tania Jain, MD, Baltimore
Mengambil pesertaFasa 1
6 Months – 80 Years · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT02203903Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 120 · Semua jantina · Dikemas kini 23 Jul 2026 · NCT05588154Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
1 Day – 120 Years · Semua jantina · Dikemas kini 23 Jul 2026 · NCT05350748Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Maryland Medical Center (UMMC), Baltimore
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Jul 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatian
1 Month – 120 Years · Semua jantina · Dikemas kini 6 Jul 2026 · NCT07019155CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jul 2026 · NCT04050280Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jun 2026 · NCT04068597A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 24 Mac 2026 · NCT04988555A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Johns Hopkins School of Medicine, Baltimore
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT05735184Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Johns Hopkins University, Baltimore
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 hingga 120 · Semua jantina · Dikemas kini 25 Jul 2025 · NCT05237258Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.